The Allergic Problem

Each year, more than 50 million Americans suffer from allergic diseases including rhinitis, sinusitis, dermatitis, asthma, food allergy and anaphylaxis.

People with allergies develop adverse immunological reactions to normally harmless substances. Many factors commonly found in the environment can provoke an allergic response. Common grass and tree pollens, mold spores, house dust mites, cockroaches, and animal dander (shed skin, fur, or feathers) are among the most common allergens. They can enter the body through a number of routes: ingestion, inhalation, injection, or bites.

Allergies cause symptoms – congestion, itching, coughing, sneezing, watery eyes, wheezing, inflammation and fatigue. Allergies that start as eczema or gastrointestinal problems can evolve into asthma. These symptoms clearly affect the quality of life of patients, and in some cases, can be life-threatening and lead to a condition known as anaphylaxis.

Investigational LAMP-Vax Therapeutic Vaccines

Dosing Regimen

As currently being tested, LAMP-Vax is delivered using a low number of immunizations (eight or less). This is meant to provide an alternative to the 100 or more allergy shots that are often required.

Exposure to Allergens through Therapy

Bu virtue of the way that LAMP-Vax nucleic acid vaccines process the allergen, they are designed not to expose subjects to free allergen. This could be a featured that reduces the risk of treatment-related adverse immune reactions, potentially including anaphylaxis, often seen with standard immunotherapy approaches that involve injecting actual allergen.

Proposed Mechanism

Immunotherapy often involves creation of “tolerance” – a process that incorporates a different set of immune cells than what LAMP-Vax is designed to do. LAMP-Vax aims to reverses the “net allergic charge” in the immune system, moving from an IgE / Th2 allergenic response to an IgG / Th1 response. To support this hypothesis, we have observed a strong Th1 response to potent allergens like flea, red cedar and peanut, following LAMP-Vax immunotherpy in model animal systems.

Japanese Red Cedar

The Japanese red cedar tree is a cultural symbol in Japan, but its pollen is a national scourge. An estimated 25% of the Japanese population, more than 25 million individuals, are allergic to Japanese red cedar pollen. ASP4070 (formerly known as JRC-LAMP-Vax) is an investigational vaccine for treating patients with Japanese cedar pollen allergies. Astellas Pharmaceuticals, Inc is leading the clinical development of ASP4070 in Japan, where it has exclusive rights for commercial development, marketing and sales.

ASP4070TM Vaccine Key Features:

  • ASP4070 is a vaccine intended to treat patients with rhino-conjunctivitis caused by allergic reaction to red cedar pollen
  • Immunotherapy to treat allergy believed not to expose patient to free allergen
  • Our LAMP-Vax vaccine allergy therapy is expected to require only 4 shots, not 100 or more often required for traditional, extract-based immunotherapy

This vaccine has been designed and tested in two species and has completed Phase 1 testing in the US and Japan.


Learn more about the clinical trials for Red Cedar Pollen allergy.

Research Article: CryJ-LAMP DNA Vaccines for Japanese Red Cedar Allergy Induce Robust Th1-Type Immune Responses in Murine Model


Learn more about the clinical trial for Peanut allergy.

Peanut Allergies

Food allergies cause over 30,000 incidents of anaphylaxis and 100 – 200 deaths in the US each year. Peanut allergy is highly problematic, with more than 1.5 million Americans impacted; life-threatening anaphylaxis can be induced by trace exposure. A diagnosis of peanut allergy means maintaining constant dietary vigilance to reduce the risk of accidental peanut-induced anaphylaxis. In the case of children, this vigilance must also be maintained by parents, schools, and other guardians.

There is no FDA-approved treatment for preventing dangerous peanut-induced allergic reactions. Immunotherapy, or administering increasing doses of an allergen to induce tolerance, leads to adverse reactions in the majority of patients undergoing peanut immunotherapy. There is a dire need for effective treatments that can provide lasting protection.


ASP0892 (formerly known as ARA-LAMP-Vax) is an investigational vaccine for treating patients suffering with food allergies to peanut, one of the most potent and problematic food allergies in the world. Astellas Pharmaceuticals, Inc is leading the full development of ASP0892, as part of the exclusive licensing agreement for LAMP-Vax platform signed/executed on October 2015.


ASP0892™ (formerly ARA-LAMP-Vax) is a novel hypoallergenic treatment that aims to significantly reduce or eliminate sensitivity to the three major peanut allergens. By directing the synthesized peanut allergen-LAMP fusion protein directly into the MHC-II lysosome compartment, ASP0892 is designed to generate a Th1–mediated immune response without exposing the patient systemically to free, native peanut allergen.


Learn more about the clinical trial for Peanut allergy.



Reversing the “net allergic charge” and changing an IgE / Th2 allergic response into an IgG / Th1 response


Generating high affinity tumor antigen specific T cells supported by CD4 helper T-cells


Trafficking antigens into the MHC-II compartment for direct, antigen specific activation of CD4+ T cells